Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment
Dementia and Geriatric Cognitive Disorders Extra · 12.03.2019 · 9 (1) · 100-113
DOI: 10.1159/000496920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dementia and Geriatric Cognitive Disorders Extra, online erschienen am 12.03.2019. Verfasst von Jung Eun Park und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, Chosun University, Gwangju, Republic of Korea. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomarkers to identify prodromal AD and very early stage of AD dementia. We aimed to identify the cutoff values of cerebrospinal fluid (CSF) biomarkers for detecting prodromal AD.
Methods
We assessed 56 patients with amnestic mild cognitive impairment (aMCI) who underwent lumbar puncture. Additionally, 87 healthy elderly individuals and 34 patients with AD dementia served as controls. Positron emission tomography was performed using florbetaben as a probe. We analyzed the concentration of Aβ1–42, total tau protein (t-Tau), and tau protein phosphorylated at threonine 181 (p-Tau181) in CSF with INNOTEST enzyme-linked immunosorbent assay.
Results
For the detection of prodromal AD in patients with aMCI, the cutoff values of CSF Aβ1–42, t-Tau, and p-Tau181 were 749.5 pg/mL, 225.6 pg/mL, and 43.5 pg/mL, respectively. To discriminate prodromal AD in patients with aMCI, the t-Tau/Aβ1–42 and p-Tau181/Aβ1–42 ratios defined cutoff values at 0.298 and 0.059, respectively.
Conclusions
CSF biomarkers are very useful tools for the differential diagnosis of prodromal AD in aMCI patients. The concentration of CSF biomarkers is well correlated with the stages of the AD spectrum.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Science, Chosun University, Gwangju, Republic of Korea.
- BK21-PLUS Research Team for Bioactive Control Technology, Chosun University, Gwangju, Republic of Korea.
- National Research Center for Dementia, Chosun University, Gwangju, Republic of Korea.
- Department of Neurology, Chonnam National University Hospital, Gwangju, Republic of Korea.
- Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea.
- Department of Neurology, School of Medicine, Chosun University, Gwangju, Republic of Korea.
Zitieren
APA
Park, J. E., Choi, K. Y., Kim, B. C., Choi, S. M., Song, M. K., Lee, J. J., Kim, J., Song, H. C., Kim, H. W., Ha, J. M., Seo, E. H., Song, W. K., Park, S. G., Lee, J. S., & Lee, K. H. (2019). Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders Extra, 9(1), 100-113. https://doi.org/10.1159/000496920
Vancouver
Park JE, Choi KY, Kim BC, Choi SM, Song MK, Lee JJ, et al. Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders Extra. 2019;9(1):100-113. doi:10.1159/000496920
BibTeX
@article{Park2019,
author = {Park, Jung Eun and Choi, Kyu Yeong and Kim, Byeong C and Choi, Seong-Min and Song, Min-Kyung and Lee, Jang Jae and Kim, Jahae and Song, Ho-Chun and Kim, Hoo-Won and Ha, Jung-Min and Seo, Eun Hyun and Song, Woo Keun and Park, Sung-Gyoo and Lee, Jung Sup and Lee, Kun Ho},
title = {Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment},
journal = {Dementia and Geriatric Cognitive Disorders Extra},
year = {2019},
volume = {9},
number = {1},
pages = {100--113},
doi = {10.1159/000496920}
}
EUVIMED